Document is current
Any future updates will be listed below
-
Authors
Kagiou, Chrysanthi https://orcid.org/0000-0002-2795-1194
Cisneros, Jose A. https://orcid.org/0000-0003-3679-7878
Farnung, Jakob https://orcid.org/0000-0002-4619-3421
Liwocha, Joanna
Offensperger, Fabian https://orcid.org/0009-0008-4304-2346
Dong, Kevin
Yang, Ka https://orcid.org/0000-0001-8937-7397
Tin, Gary https://orcid.org/0009-0005-1298-3221
Horstmann, Christina S.
Hinterndorfer, Matthias
Paulo, Joao A. https://orcid.org/0000-0002-4291-413X
Scholes, Natalie S. https://orcid.org/0000-0002-1053-4079
Sanchez Avila, Juan https://orcid.org/0000-0002-5920-7618
Fellner, Michaela
Andersch, Florian
Hannich, J. Thomas https://orcid.org/0000-0002-2286-4956
Zuber, Johannes https://orcid.org/0000-0001-8810-6835
Kubicek, Stefan https://orcid.org/0000-0003-0855-8343
Gygi, Steven P. https://orcid.org/0000-0001-7626-0034
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
- License Information
-
More Information
Article History
Received: 29 January 2024
Accepted: 18 June 2024
First Online: 26 June 2024
Competing interests
: S.K. and G.E.W. are scientific founders and shareholders of Proxygen and Solgate. G.E.W. is on the Scientific Advisory Board of Nexo Therapeutics. The Winter lab received research funding from Pfizer. B.A.S. is a member of the scientific advisory boards of Proxygen and BioTheryX, and a co-inventor of intellectual property licensed to Cinsano. The remaining authors declare no competing interests.
